MarauderVoyager38
33分前
https://www.yahoo.com/news/bill-ban-mrna-vaccines-passes-140200324.html
-House Bill 371, sponsored by Rep. Greg Kmetz and co-sponsored by Reps. Tracy Sharp and Lukas Schubert, aims to ban mRNA vaccines, including those for Covid-19, due to safety concerns.
-The bill passed out of the House Judiciary Committee in a 12-8 vote and is now headed to the House floor for further consideration.
-Supporters of the bill argue that mRNA vaccines are harmful, while opponents believe they are safe and removing them limits individual choice in healthcare.
JoeForkeyBolo
2月前
Item 2.01 Completion of Acquisition or Disposition of Assets.
On December 30, 2024, Novavax CZ a.s. (the “Seller”), an indirect, a wholly owned subsidiary of Novavax Inc. (the “Company”), completed the previously-announced sale of the Company’s biologics manufacturing campus located at Bohumil, Jevany, Czech Republic (the “Facility”) to Novo Nordisk Production Czech s.r.o. (the “Purchaser”), pursuant to an asset purchase agreement, dated as of December 3, 2024 (the “Asset Purchase Agreement”), by and among the Seller, the Company, the Purchaser and Novo Nordisk A/S. Pursuant to the Asset Purchase Agreement, the Seller sold, transferred and assigned to the Purchaser: (i) properties owned by the Seller registered on folio No. 894 maintained by the Cadastral Office for Central Bohemian Region, Detached Cadastral Office Prague-East, for the cadastral area Jevany, comprising land in the settlement known as Bohumil, as well as certain moveable assets and equipment located at the manufacturing facility (the “Transferred Assets”); (ii) contracts related to the operation and management of the Transferred Assets (the “Transferred Contracts”); and (iii) certain employees currently providing services related to the Transferred Assets (the “Transferred Employees”). The total purchase price for the Facility was $200 million and the assumption by the Purchaser of liabilities (on a look-forward basis) pertaining to the Transferred Assets, Transferred Contracts and Transferred Employees. On the closing date, the Purchaser received a cash payment of $180 million, net of the initial payment of $10 million made in September 2024 and $10 million placed in an escrow account to be released to the Seller on the date which is 12 months following the closing date (subject to adjustment for any claims the Purchaser may have against the Seller under the Asset Purchase Agreement). Pursuant to the terms of the Asset Purchase Agreement, the Company was also reimbursed approximately $2. 6 million, subject to adjustments, for costs in continuing to operate and maintain the Transferred Assets, Transferred Contracts and Transferred Employees between December 3,2024 and the completion of the sale.
The foregoing description of the Asset Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Asset Purchase Agreement, which will be filed with the Securities and Exchange Commission as an exhibit to the Company’s Annual Report on Form 10-K for the year ending December 31, 2024.
https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318815916&type=HTML&symbol=NVAX&cdn=742ca96f5c4d25df192d823f151d9c8a&companyName=Novavax+Inc.&formType=8-K&dateFiled=2024-12-30
JoeForkeyBolo
2月前
NEWS: Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
• Novavax continues to progress Sanofi agreement by achieving first milestone, with additional milestones and ongoing tiered royalties to come, solidifying a strong model for future partnerships
• Novavax's COVID-19 vaccine included in Sanofi's two combination vaccine candidates for prevention of influenza and COVID-19, for which Phase 1/2 trials were initiated and Fast Track designation recently granted in the U.S.
GAITHERSBURG, Md., Dec. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its partnership with Sanofi. The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi.
"Novavax is steadily advancing our new corporate growth strategy. By achieving this milestone in our collaboration agreement with Sanofi, as well as the upcoming sale of our Czech Republic manufacturing site, we are strengthening our balance sheet as well as delivering significant cost reductions," said John C. Jacobs, President and Chief Executive Officer, Novavax. "In addition, Sanofi recently announced it received U.S. FDA Fast Track designation for two vaccine candidates combining our proven COVID-19 vaccine with its market-leading influenza vaccines. These assets have progressed to Phase 1/2 clinical trials, with the potential for future Novavax milestone payments and royalties, if successful."
The $50 million milestone is the first following the initial upfront payment at signing of the agreement with Sanofi in May 2024. Following this payment, there are additional potential milestones of up to $300 million related to Novavax's partnered COVID-19 vaccine that will be recognized in the periods when earned. In addition to milestones for the stand-alone COVID-19 vaccine, the agreement also includes combination products developed by Sanofi including Novavax's COVID-19 vaccine, which present a potential opportunity of up to an additional $350 million for Novavax in future milestones. In addition, both stand-alone COVID-19 sales and potential sales of any Sanofi combination products would net Novavax ongoing tiered royalties. Further, Novavax is eligible to receive up to $200 million for the first four products created by Sanofi utilizing its Matrix-M adjuvant, and up to $210 million in milestone payments for each product including Matrix-M thereafter, plus ongoing royalties for all Sanofi products utilizing Matrix-M.
Novavax's corporate growth strategy includes efforts to pursue additional partnerships for its late-stage and early-stage Research and Development assets and Matrix-M adjuvant alone. This growth strategy should position the Company for ongoing value creation as additional partnerships are secured under a similar contractual framework.
https://ir.novavax.com/press-releases/2024-12-13-Novavax-Advances-Corporate-Growth-Strategy-Through-Sanofi-Partnership,-Including-Achievement-of-First-50-Million-Milestone
JoeForkeyBolo
2月前
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
Zacks Equity Research
Wed, December 11, 2024
Sanofi SNY announced that the FDA has granted a Fast Track designation to two combination vaccine candidates to prevent influenza and COVID-19 infections in people aged 50 years and above.
NCT06695117, the first vaccine candidate, combines SNY’s influenza protein-based trivalent vaccine, Fluzone High-Dose and Novavax’s NVAX adjuvanted recombinant Novavax COVID-19 vaccine, NVXC19.
NCT06695130, the second vaccine candidate, combines SNY’s influenza recombinant protein-based trivalent vaccine, Flublok with NVXC19.
SNY markets Fluzone High-Dose and Flublok flu vaccines.
Novavax recently signed a multi-billion dollar deal with Sanofi for its protein-based COVID-19 vaccine.
Per the deal, from 2025 onwards, Sanofi will gain rights to co-market Novavax’s COVID-19 vaccine globally, except in certain countries where the company has existing partnership agreements. The French drugmaker also has the sole license to develop and market the Novavax vaccine in combination with its influenza vaccine.
Year to date, shares of Sanofi have lost 3.3% against the industry’s growth of 8.9%.
More on SNY's Combination Vaccine Candidates
Per the company, NCT06695117 and NCT06695130 are the first non-mRNA combination vaccine candidates that include two licensed vaccines for the prevention of influenza and COVID-19 infections.
When administered as a booster dose, Novavax’s NVXC19 has also demonstrated a better tolerability profile than the currently available mRNA COVID-19 vaccines.
NVXC19 has also demonstrated high efficacy against COVID-19 as a primary vaccination in two phase III studies.
Two ongoing phase I/II studies are currently evaluating the safety profile and immune response induced by NCT06695117 and NCT06695130.
SNY Boasts a Strong Vaccine Segment
Sanofi possesses one of the world’s leading vaccine operations, with total annual sales of more than €5 billion in the past five years. The company’s Vaccine unit has delivered mid-to-high-single-digit sales growth since 2018. SNY also has a strong position in both seasonal and pre-pandemic influenza vaccine spaces.
In the first nine months of 2024, the Vaccines unit generated sales worth €6.12 billion increasing 14.5% year over year at a constant currency rate.
Sanofi has at least five vaccine candidates, which are expected to enter phase III development by 2025. SNY expects annual net sales to be more than €10 billion from its Vaccines unit by 2030 backed by the company’s innovation efforts. Sanofi continues to expand its vaccine business further.
Other Players Developing COVID-Flu Combination Shots
Apart from Sanofi, Moderna MRNA and Pfizer PFE are also developing their respective COVID/flu combination vaccines using mRNA technology.
Moderna is developing mRNA-1083, its investigational mRNA-based combination vaccine against influenza and COVID-19. In June, MRNA announced that the phase III study evaluating its COVID/flu combination vaccine, mRNA-1083, in older adults (50 years and older) met the primary endpoints.
Subject to discussions with the FDA, Moderna plans to submit a regulatory filing, seeking approval for the COVID/flu combination vaccine shortly.
Meanwhile, Pfizer suffered a major setback in August when it reported data from a phase III study on its investigational mRNA-based COVID/flu combination vaccine. The study missed one of its two primary immunogenicity objectives.
PFE is currently evaluating adjustments to its combination vaccine program and plans to discuss the next steps with health authorities. Pfizer is developing this vaccine in collaboration with BioNTech.
https://finance.yahoo.com/news/fda-grants-fast-track-tag-152500888.html
JoeForkeyBolo
2月前
NEWS: Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
December 10, 2024
• Company continuing to work with the U.S. FDA on potential for accelerated approval pathway
• Novavax intends to partner on both candidates to advance to filing and commercialization
GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the first participants have been dosed in its COVID-19-Influenza Combination (CIC) and stand-alone seasonal influenza Phase 3 trial. The trial will evaluate the immunogenicity and safety of the CIC and stand-alone seasonal influenza vaccine candidates compared to Novavax's updated 2024-2025 COVID-19 vaccine (NVX-CoV2705) and a licensed seasonal influenza vaccine comparator in adults aged 65 and older.
"A combination vaccine for two vaccine-preventable diseases is an important step forward for public health and the trial start is a key step in advancing our late-stage pipeline, which we plan to progress through strategic partnerships," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President, Head of Research and Development, Novavax. "Our goal is to get these assets to market as soon as possible, and we will work with the U.S. FDA to assess the possibility of an accelerated approval pathway."
The Company is working with the U.S. Food and Drug Administration (FDA) to determine the potential of the current CIC and stand-alone influenza trial to support accelerated approval. While in the process of seeking alignment on accelerated approval criteria with the U.S. FDA, Novavax has decided to recruit an initial cohort of approximately 2,000 participants while continuing this dialogue. Novavax anticipates being able to provide more clarity and information on potential next steps by Q2 2025, including if additional clinical work would be needed to achieve registration for these assets.
The randomized Phase 3 trial builds on positive Phase 2 data and aims to further evaluate the immunogenicity and safety of a combination of Novavax's updated 2024-2025 COVID-19 vaccine, trivalent nanoparticle stand-alone seasonal influenza vaccine candidate and patented saponin-based Matrix-M adjuvant relative to separate administrations of Novavax's updated 2024-2025 COVID-19 vaccine and a licensed seasonal influenza vaccine comparator. In addition, the trial also aims to further evaluate the immunogenicity and safety of Novavax's stand-alone influenza vaccine, also containing Matrix-M.
The Company's FY 2025 financial guidance for combined Research & Development and Selling, General and Administrative expense of approximately $500 million is inclusive of this CIC and stand-alone influenza initial planned Phase 3 clinical activity and is subject to revisions and updates as next steps are determined.
https://ir.novavax.com/press-releases/2024-12-10-Novavax-Initiates-Phase-3-Trial-for-COVID-19-Influenza-Combination-and-Stand-Alone-Influenza
JoeForkeyBolo
2月前
NEWS: Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million
• Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform
• Provides Novavax with $190 million cash payment in 2024 and additional $10 million in 2025, and annual operating cost reductions of approximately $80 million
GAITHERSBURG, Md., Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk for $200 million. The agreement includes a transfer of assets, including a 150,000-square foot state-of-the-art recombinant protein manufacturing facility with support buildings, along with the existing workforce and all related and required infrastructure.
The agreement provides Novavax with significant, non-dilutive capital, further enabling the Company to advance its corporate growth strategy to drive value from its early- and late-stage pipeline using its proven technology platform, consisting of Matrix-M adjuvant and nanoparticle protein-based technology. In addition to the $190 million cash payment in 2024 and additional $10 million in 2025, Novavax expects the sale of the facility to result in annual operating cost reductions of approximately $80 million.
"The decision to sell the Czech Republic manufacturing facility aligns with our previously announced commitment to evolve Novavax into a more lean and agile organization focused on partnering our pipeline assets and technology platform," said John C. Jacobs, President and Chief Executive Officer, Novavax. "We are thankful to our dedicated colleagues in the Czech Republic who have contributed to Novavax's mission of delivering our technology to address unmet needs. We look forward to working with Novo Nordisk to ensure a successful transition."
Following closure of the agreement, expected by December 30, 2024, full responsibility for the manufacturing facility will be transferred to Novo Nordisk.
https://ir.novavax.com/press-releases/2024-12-04-Novavax-Announces-Sale-of-Czech-Republic-Manufacturing-Site-to-Novo-Nordisk-for-200-Million
JoeForkeyBolo
3月前
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., Nov. 15, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company granted a non- qualified stock option and restricted stock units to Ruxandra Draghia-Akli, MD, PhD, its newly appointed Executive Vice President and Head of Research & Development, as a material inducement for her entry into employment with Novavax, effective as of November 11, 2024 (the "grant date"). These awards were approved by the Compensation Committee of Novavax and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Novavax, Inc. 2023 Inducement Plan.
The non-qualified stock option is an option to purchase 64,150 shares of Novavax's common stock with a per share exercise price of $9.01, the closing price of Novavax's common stock on the Nasdaq Global Select Market on the grant date. The non- qualified stock option has a ten-year term and will vest as to one-quarter of the underlying shares on the first anniversary of the grant date, and as to the remaining shares in equal monthly installments for 36 months thereafter, in each case generally subject to Dr. Draghia-Akli's continued employment with Novavax through the applicable vesting date. The restricted stock units are with respect to 42,770 shares of Novavax's common stock and will vest as to one-third of the restricted stock units on each of the first three anniversaries of the grant date, in each case generally subject to Dr. Draghia-Akli 's continued employment with Novavax through the applicable vesting date. The non-qualified stock option and restricted stock units are subject to the terms and conditions of the Novavax, Inc. 2023 Inducement Plan.
https://ir.novavax.com/press-releases/2024-11-15-Novavax-Announces-Grant-of-Inducement-Awards-Pursuant-to-Nasdaq-Listing-Rule-5635-c-4
JoeForkeyBolo
3月前
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
GAITHERSBURG, Md., Nov. 11, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared the Company to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical hold issues. Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible.
"We thank the FDA for their partnership and thorough review of the additional information provided as part of our response package," said Robert Walker, MD, Chief Medical Officer, Novavax. "The information provided to the FDA supported our assessment that the serious adverse event was not related to our vaccine. We plan to start our Phase 3 trial as soon as possible."
The clinical hold announced on October 16, 2024, resulted from a spontaneous report of a serious adverse event in a participant who received investigational CIC vaccine in a Phase 2 trial that completed in 2023. The FDA had requested additional information on this event, initially reported as motor neuropathy. The additional information included a change in the event term to amytrophic lateral sclerosis, a condition that is not known to be immune-mediated or associated with vaccination, which in this event was assessed as not related to vaccination.
https://ir.novavax.com/press-releases/2024-11-11-U-S-FDA-Removes-Clinical-Hold-on-Novavaxs-COVID-19-Influenza-Combination-and-Stand-alone-Influenza-Phase-3-Trial
JoeForkeyBolo
3月前
Form 8-K Filing
Item 1.01 Entry into a Material Definitive Agreement.
On November 1, 2024, Novavax, Inc. (the “Company”) and The Secretary of State for Health and Social Care, acting as part of the Crown, through the UK Health Security Agency (the “Authority”), entered into a Termination and Settlement Agreement (the “Settlement Agreement”) and a Letter of Amendment to the Settlement Agreement (the “Settlement Agreement Amendment”), relating to the Amended and Restated SARS-COV-2 Vaccine Supply Agreement effective July 1, 2022 (the “Amended and Restated Supply Agreement”) by and between the Company and the UK Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the Crown, settling the disputes regarding the Amended and Restated Supply Agreement and releasing both parties of all claims arising out of or connected with the Amended and Restated Supply Agreement.
Under the terms of the Settlement Agreement, the Authority and the Company agreed to terminate the Amended and Restated Supply Agreement and to fully settle the outstanding amount under dispute related to upfront payments previously received by the Company from the Authority under the Amended and Restated Supply Agreement. Pursuant to the Settlement Agreement, the Company agreed to pay a refund of $123.8 million (the “Settlement Payment”) to the Authority in equal quarterly installments of 10.3 million over a three year period, ending on June 30, 2027. The Settlement Payment amount includes a $11.3 million provision for interest over the period and may be avoided if the Company chooses to accelerate payments. Under the terms of the Settlement Agreement Amendment, the Authority and the Company agreed to make the first quarterly installment payment due on November 30, 2024.
The foregoing descriptions of the material terms of the Settlement Agreement and the Settlement Agreement Amendment does not purport to be complete and is qualified in its entirety by reference to the Settlement Agreement, which will be filed with the Securities and Exchange Commission as an exhibit to the Company’s Annual Report on Form 10-K for the year ended J December 31, 2024.
Item 1.02 Termination of a Material Definitive Agreement.
In connection with the parties’ entry into the Settlement Agreement, the Company and the Authority terminated the Amended and Restated Supply Agreement.
The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference in this Item 1.02.
Form 8-K
JoeForkeyBolo
3月前
Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024.
Details of the event and replay are available at the link below:
https://ir.novavax.com/press-releases/2024-11-04-Novavax-to-Host-Conference-Call-to-Discuss-Third-Quarter-2024-Financial-Results-and-Operational-Highlights-on-November-12,-2024
cowtown jay
3月前
"Vanguard Group Inc ownership in NVAX / Novavax, Inc.
2024-11-04 - Vanguard Group Inc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 15,430,034 shares of Novavax, Inc. (US:NVAX). This represents 9.63 percent ownership of the company. In their previous filing dated 2024-02-13 , Vanguard Group Inc had reported owning 14,560,054 shares, indicating an increase of 5.98 percent."
https://fintel.io/so/us/nvax/vanguard-group
https://www.sec.gov/Archives/edgar/data/102909/000093247124000542/UnitedStates_13G__NovavaxInc.txt
JoeForkeyBolo
3月前
NEWS: Åsa Manelius Named Managing Director of Novavax AB Site
November 4, 2024
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Åsa Manelius, will join the Company in February 2025 as Managing Director of the Novavax AB site in Uppsala, Sweden, the primary manufacturing site for Matrix-M.
Ms. Manelius brings more than 25 years of experience leading global operations and most recently worked at AstraZeneca in Södertälje, leading the global supply chain for its Respiratory & Immunology therapy area. Prior to this role, she served as the General Manager of AstraZeneca’s Sweden Biologic Center, a global commercial and strategic launch site for biological medicines.
“Åsa brings deep global operations knowledge to Novavax during a critical time of transition for the Company,” said Rick Crowley, Chief Operations Officer, Novavax. “As we focus on driving value via our proven technology platform through partnerships and R&D, Åsa and our AB site will be critical to ensuring robust supply of our best-in-class Matrix-M™ adjuvant for both our pipeline and potential partners.”
“I’m excited to join Novavax and look forward to bringing my deep expertise in development, CMC activities and manufacturing operations to its adjuvant business,” said Ms. Manelius. “There is tremendous potential in Novavax’s Matrix-M™ technology, and I look forward to working with the team to create a true center of excellence in Uppsala.”
Ms. Manelius previously served as Managing Director at Biora AB and in executive leadership roles at Pfizer Health AB. She received an MSc/Chemical Engineering and a PhD in Biotechnology/Biochemical Engineering from Lund University.
https://ir.novavax.com/press-releases/Asa-Manelius-Named-Managing-Director-of-Novavax-AB-Site
JoeForkeyBolo
4月前
NEWS: Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
October 16, 2024
GAITHERSBURG, Md., Oct. 16, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The clinical hold is due to a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a single CIC Phase 2 trial participant outside of the U.S. who received the vaccine in January 2023. The trial completed in July 2023 and the participant reported the SAE in September 2024.
"We are working closely with the FDA to provide the necessary information that will allow them to better understand this observation and resolve the clinical hold," said Robert Walker, MD, Chief Medical Officer, Novavax. "It is important to note that safety is our top priority, and while we do not believe causality has been established for this serious adverse event, we are committed to working expeditiously to fulfill requests for more information from the FDA. Our goal is to successfully resolve this matter and to start our Phase 3 trial as soon as possible."
Data from Novavax's previous COVID-19 and influenza trials have shown no signals for motor neuropathy. Investigators have been informed of this action. The COVID-19 IND for Novavax's COVID-19 vaccine is not impacted by the clinical hold.
https://ir.novavax.com/press-releases/2024-10-16-Update-on-Novavaxs-COVID-19-Influenza-Combination-and-Stand-alone-Influenza-Phase-3-Trial
Also, Form 8-K filed with SEC.
JoeForkeyBolo
4月前
Novavax Poised for U.S. Market Capture and Cost Efficiency Gains: A Resounding Buy Rating
https://markets.businessinsider.com/news/stocks/novavax-poised-for-u-s-market-capture-and-cost-efficiency-gains-a-resounding-buy-rating-1033671123
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Novavax (NVAX – Research Report) today and set a price target of $23.00.
Mayank Mamtani has given his Buy rating due to a combination of factors surrounding Novavax’s strategic positioning and operational progress. He highlights the company’s readiness to capture the U.S. commercial COVID market for the upcoming Fall ’24 season, strengthened by finalized retail pharmacy contracts covering over 17,000 locations—a significant increase from the prior fiscal year. Additionally, Mamtani notes Novavax’s effective recalibration of its cost structure, which has led to a substantial reduction in operating expenses, and anticipates further cost savings in the future. These improvements in operational efficiency, coupled with the company’s plan to strategically exit most ex-U.S. territories, reinforce the analyst’s positive outlook on Novavax’s stock.
Furthermore, the potential for regulatory and commercial success of Novavax’s late-stage pipeline, particularly the COVID-influenza combination vaccine and stand-alone flu programs, underpins the Buy rating. Mamtani emphasizes the company’s alignment with FDA plans for a single Phase III immunogenicity study, which could expedite the approval process. He also points out the anticipated milestone payments from the partnership with Sanofi, which are expected to bolster Novavax’s financial position. Despite a downward revised FY24 guidance, largely due to the exclusion of future Advance Purchase Agreements (APAs), Mamtani’s analysis suggests confidence in Novavax’s ability to navigate the market and capitalize on its U.S. commercial strategy and pipeline advancements, justifying a Buy rating with a price target of $23.
JoeForkeyBolo
5月前
Novavax Stock Gains Retail Spotlight After Jefferies’ Bullish Call, Firm’s Subsequent Clarification: Retail Turns Exuberant
Bhavik Nair·Stocktwits
Published Oct 3, 2024
The brokerage reportedly indicated that it caught up with Novavax management and believes that for the near term, the firm is in "a good position" to meet its 2024 revenue guidance.
Novavax Inc (NVAX) stock became the second most trending ticker on Stocktwits on Thursday morning after Jefferies gave a ‘Buy’ rating to the stock with a price target of $31. The target represents a potential upside of over 100% from the stock’s current level.
The brokerage reportedly indicated that it caught up with Novavax management and believes that for the near term, the firm is in "a good position" to meet its 2024 revenue guidance, driven by the U.S. market. Jefferies also reportedly said that according to the company, a majority of the 24/25 COVID-19 season sales will be in Q4.
“For the long term, the company is transitioning to an R&D model, with Phase 3 flu +/- CV19 as the lead that could trigger a major partnership in 2025 and new non-seasonal vaccines based on unique adjuvant technology as an earlier pipeline that would drive significant future growth,” Jefferies reportedly said.
Following the update, shares of Novavax had closed over 19% higher on Wednesday. However, Novavax came out with a clarification in an SEC filing.
The firm stated that it is aware of an analyst report published on Oct. 1, 2024, which referred to discussions with Novavax’s management regarding the anticipated U.S. market for COVID-19 vaccination for the 2024-2025 vaccination season.
“Novavax would like to clarify that while it has anticipated the COVID-19 vaccination market in the U.S. will be similar to last year, it has neither updated nor reaffirmed its full year 2024 financial guidance issued on August 8, 2024,” it clarified.
Shares of Novavax were trading over 5% lower in Thursday’s pre-market session. However, retail investors on Stocktwits turned ‘extremely bullish’ (80/100) from ‘bearish’ a day ago.
Notably, Novavax shares are up over 191% since the beginning of the year, significantly outperforming the benchmark indices. Stocktwits users with a ‘bullish’ outlook believe the shares are likely to rally in the coming times.
https://stocktwits.com/news-articles/markets/equity/novavax-stock-in-focus-after-bullish-takes-from-jefferies/cJccSbkR3r
JoeForkeyBolo
5月前
Novavax Form 8-K filed 10/3/24
Form 8-K
Novavax, Inc. (“Novavax”) is aware of an analyst report published on October 1, 2024, which referred to discussions with Novavax’s management regarding, among other things, the anticipated U.S. market for COVID-19 vaccination for the 2024-2025 vaccination season. Novavax would like to clarify that while it has anticipated the COVID-19 vaccination market in the U.S. will be similar to last year, it has neither updated nor reaffirmed its full year 2024 financial guidance issued on August 8, 2024.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Monksdream
2月前
